256 related articles for article (PubMed ID: 328244)
1. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease.
Savery F
Dis Nerv Syst; 1977 Aug; 38(8):605-8. PubMed ID: 328244
[TBL] [Abstract][Full Text] [Related]
2. A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
Diamond SG; Markham CH; Treciokas LJ
Ann Neurol; 1978 Mar; 3(3):267-72. PubMed ID: 352236
[TBL] [Abstract][Full Text] [Related]
3. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
[TBL] [Abstract][Full Text] [Related]
4. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
Savery F
Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863
[No Abstract] [Full Text] [Related]
5. The effects of combining carbidopa with levodopa for Parkinson's disease.
Martin WE; Tolosa ES; Loewenson RB; Lee MC; Resch JA; Baker AB
Geriatrics; 1975 Dec; 30(12):39-44. PubMed ID: 1104406
[No Abstract] [Full Text] [Related]
6. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
Lombardo L; De la Garza R
Arch Invest Med (Mex); 1977; 8(2):123-8. PubMed ID: 907417
[TBL] [Abstract][Full Text] [Related]
8. Sinemet CR in Parkinson's disease.
Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
[TBL] [Abstract][Full Text] [Related]
9. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
Londoõ R
Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
[TBL] [Abstract][Full Text] [Related]
12. Comparison of enteric-coated levodopa with levodopa-carbidopa combination. A double-blind crossover trial.
Gilligan B; Wodak J; Stark R; O'Halloran M
Med J Aust; 1979 Aug; 2(4):205-7. PubMed ID: 390336
[TBL] [Abstract][Full Text] [Related]
13. Response to Sinemet 25/100 in Parkinson's disease.
Ulm G; Gerdes U; Lehmann K
Adv Neurol; 1984; 40():541-7. PubMed ID: 6695634
[No Abstract] [Full Text] [Related]
14. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
Mark MH; Sage JI
Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
[TBL] [Abstract][Full Text] [Related]
15. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Libman I; Gawel MJ; Riopelle RJ; Bouchard S
Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
[TBL] [Abstract][Full Text] [Related]
16. [Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
Omoto T
Rinsho Shinkeigaku; 1976 Dec; 16(12):879-80. PubMed ID: 1035531
[No Abstract] [Full Text] [Related]
17. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
[TBL] [Abstract][Full Text] [Related]
18. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
19. [The additive effect of amantadine hydrochloride (Symmetrel) on parkinsonian patients receiving levodopa treatment (author's transl)].
Shiozawa R; Kase M; Kuroiwa Y; Narabayashi H; Nishitani Y; Ohmoto T; Toyokura Y; Uono K
No To Shinkei; 1981 Mar; 33(3):301-9. PubMed ID: 7018522
[No Abstract] [Full Text] [Related]
20. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
